PEGS

Kelonia Therapeutics to Participate in Upcoming Scientific Conferences

Retrieved on: 
Thursday, May 2, 2024
Oncology, Health, Genetics, Other Science, Science, Pharmaceutical, Biotechnology, Kélonia, Multiple myeloma, Date, Ex vivo, Cell, Protein, Patient, Gene, Society, PEGS, Medicine, Therapy, BCMA, Pharmaceutical industry

“Preclinical data continues to demonstrate exquisite T cell specificity and profound CAR T cell activity with low dose levels of our in vivo Gene Placement System (iGPS®),” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia.

Key Points: 
  • “Preclinical data continues to demonstrate exquisite T cell specificity and profound CAR T cell activity with low dose levels of our in vivo Gene Placement System (iGPS®),” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia.
  • “Combining this platform with our proprietary, fully-human, and highly active BCMA CAR candidate creates a medicine with the potential to transform the treatment of multiple myeloma.
  • With KLN-1010 poised to be the first in vivo CAR-T cell therapy for multiple myeloma, we aim to provide a potentially life-changing solution for patients that need it most.
  • ET
    PEGS Boston Summit – Therapeutics: In Vivo Cell and Gene Engineering
    Date and Time: Friday, May 17, 2024 at 9:30 – 10:00 a.m.

Federated Wireless Unveils Premium Enterprise-Grade Spectrum (PEGS), Elevating CBRS to Mission-Critical Reliability Levels

Retrieved on: 
Thursday, March 28, 2024
ESC, SAS, FCC, DPA, Case management, Biophysical environment, Partnership, CBRS, Wireless, KPI, Federated Wireless, TCO, PEGS, Federal, Hertz, Ecosystem, Federated, Investment, AFC, Federal Communications Commission, Mobile phone

Catering to a rapidly expanding CBRS ecosystem which boasts over 402,000 CBRS-enabled devices, Federated Wireless currently manages 45% of total enabled devices.

Key Points: 
  • Catering to a rapidly expanding CBRS ecosystem which boasts over 402,000 CBRS-enabled devices, Federated Wireless currently manages 45% of total enabled devices.
  • Servicing over 600 customers and accounts, Federated Wireless continues to introduce algorithmic improvements to its cloud-based Spectrum Access System (SAS) , enhancing performance across the CBRS ecosystem.
  • Their support and performance have elevated our capabilities, delivering unmatched reliability and support for our 3GHz licensed fixed wireless operations.”
    In response to growing demands for sophisticated spectrum solutions, Federated Wireless is launching the Premium Enterprise Grade Spectrum (PEGS) service offering.
  • Federated Wireless remains actively engaged with the Federal Communications Commission (FCC) to fine-tune CBRS regulations, thus enhancing accessibility to premium grade spectrum.

Playground - The Next Evolution in Sexual Wellness - Redefines Pleasure with New Mood Maker Intimacy Oil

Retrieved on: 
Tuesday, October 24, 2023
Maker, Female, Cordyceps, System, Fleur du Mal, Paraben, PEGS, Entrepreneurship, Condom, Propylene glycol, Vulva, Lingzhi (mushroom), Meadowfoam seed oil, Partnership, Arousal, SAN, Pleasure, Mineral oil, Withania somnifera, Hormone, Woman, Sulfate, Call-progress tone, Human, RTW, Playground, Brassica oleracea, Birth control, Gluten

SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Playground, the pioneering sexual wellness brand co-founded by Christina Aguilera, is thrilled to unveil its latest innovation, Mood Maker, a clean, pH-balanced intimacy oil that revolutionizes the way we experience pleasure. Crafted with a vagina-safe formula, Mood Maker uses botanical aphrodisiacs to promote arousal and support a healthy libido. The product marks Playground's first release following its inaugural line of clinically tested,vagina-healthy personal lubricants. Within this new product category, Playground will continue to create good-for-you pleasure essentials intentionally designed for women.

Key Points: 
  • SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Playground , the pioneering sexual wellness brand co-founded by Christina Aguilera, is thrilled to unveil its latest innovation, Mood Maker, a clean, pH-balanced intimacy oil that revolutionizes the way we experience pleasure.
  • Crafted with a vagina-safe formula, Mood Maker uses botanical aphrodisiacs to promote arousal and support a healthy libido.
  • Within this new product category, Playground will continue to create good-for-you pleasure essentials intentionally designed for women.
  • Prioritizing vaginal health over topical irritants, Mood Maker is a botanical masterpiece designed to enhance pleasure, kindle desire, and support a healthy libido.

Orna Therapeutics Unveils Progress of Circular RNA Platform and Improvements in Lead Program ORN-101 at PEGS and ASGCT

Retrieved on: 
Thursday, May 18, 2023
PEGS, IRES, Therapy, Gene, Biotechnology, Infection, Ornäs, Force, DSM-IV codes, RNA, Element, Doctor of Philosophy, Immunotherapy, Messenger, CAR, Patient, Annual general meeting, Cell, American Society of Gene and Cell Therapy, Neoplasm, LNP, Protein, Society, Vaccine, Orna

CAMBRIDGE, Mass., May 18, 2023 /PRNewswire/ -- Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, presented data on the progress of lead program ORN-101, a development-stage in situ CAR program, at the Protein Engineering Summit (PEGS) and at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles.

Key Points: 
  • The presentations include a session and talk at PEGS, as well as a poster presentation at ASGCT, which may be viewed on the Orna website here .
  • "Using the Orna FoRCE platform, we've been able to develop ORN-101, a potent anti-cancer circular RNA therapy delivered via LNP," said Robert Mabry, PhD, Chief Scientific Officer at Orna.
  • These desirable features further allow oRNA therapeutics to be developed for applications beyond infectious disease, including oncology and genetic disorders.
  • ORN-101 features high expression of the CAR driven by an optimized IRES element, selected by Orna's FoRCE platform to yield durable protein expression.

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

Retrieved on: 
Monday, May 15, 2023
Immortalised cell line, PEGS, Omicron, Probability, Therapy, G protein-coupled receptor, COVID-19, Research, Operation (mathematics), Antibody, Immunotherapy, Hynes Convention Center station, Discovery, CELL, Cell, Protein engineering, Hynes Convention Center, Eurosport 1, Fine chemical, Vaccine, Beacon

EMERYVILLE, Calif., May 15, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of Beacon Select™ optofluidic system with Opto® B Discovery workflows for antibody discovery.

Key Points: 
  • Affordable two-chip Beacon Select system to broaden customer access to innovative high throughput, function-first antibody discovery capabilities
    EMERYVILLE, Calif., May 15, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of Beacon Select™ optofluidic system with Opto® B Discovery workflows for antibody discovery .
  • Combined with the value-matched Beacon Select system, more customers may access these propriety antibody discovery applications, but with the optimum level of features that meet their research and budgetary needs.
  • Opto B Discovery workflows on the Beacon Select system enable scientists to accelerate antibody screening and hit generation to find lead candidate antibodies and are ideally suited for small- to mid-sized biopharma and CDMOs/CROs.
  • To further increase customer accessibility and affordability, PhenomeX will offer the Beacon Select system for antibody discovery with different purchase options including capital placement, lease, or reagent rental.

SCIEX Announces the BioPhase 8800 Driver for Empower Software

Retrieved on: 
Monday, May 15, 2023
Mobile, Wireless, Technology, Hospitals, Health Technology, Software, Biotechnology, Internet, Pharmaceutical, Health, Data Management, CE, PEGS, Drug development, LC, Workflow, Empower, SCIEX, CDS, Data analysis, Acquisition, Medical device, QC

At PEGS 2023 , SCIEX , a global leader in life science analytical technologies, launches the BioPhase 8800 driver for Empower software, which integrates the BioPhase 8800 system with the Empower Chromatography Data System (CDS) from Waters Technologies Corporation.

Key Points: 
  • At PEGS 2023 , SCIEX , a global leader in life science analytical technologies, launches the BioPhase 8800 driver for Empower software, which integrates the BioPhase 8800 system with the Empower Chromatography Data System (CDS) from Waters Technologies Corporation.
  • Scientists can now directly control the multi-capillary BioPhase 8800 system through the Empower CDS while maintaining the experimental flexibility of SCIEX capillary electrophoresis (CE) systems.
  • This brings BioPhase 8800 system integration into standard workflows, helping to minimize method development, improve characterization and, ultimately, shorten drug development timelines.
  • The BioPhase 8800 driver for Empower software enables analytical scientists, both in regulated and non-regulated biopharma labs, to perform these tasks, all from a single software solution.

Insilico Medicine Founder and CEO to Give Keynote on Disease Modeling with AI at PEGS Boston

Retrieved on: 
Friday, May 12, 2023
Pharma, Idiopathic pulmonary fibrosis, PEGS, Partnership, Drug development, COVID-19, Nature Communications, Intelligence, History, Doctor of Philosophy, Hynes Convention Center station, Fibrosis, Algorithm, Insilico Medicine, Artificial intelligence, Drug discovery, Protein engineering, Hynes Convention Center, Research, Microsoft Development Center Norway, Medicine, Pharmaceutical industry, Medical device, Science, Oncotarget

Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that Alex Zhavoronkov, PhD, founder and CEO of the Company, will attend the PEGS Boston Summit from May 15-19.

Key Points: 
  • Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that Alex Zhavoronkov, PhD, founder and CEO of the Company, will attend the PEGS Boston Summit from May 15-19.
  • A team of expert scientists are developing Pharma.AI at the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region’s largest AI-powered biotechnology research center.
  • “We are at an exciting moment in the history of generative AI in drug discovery,” says Zhavoronkov.
  • In total, Insilico has 31 programs across 29 targets, including in fibrosis, oncology, immunology, and central nervous system disorders.

PhenomeX To Participate in 19th Annual PEGS Boston Conference & Expo

Retrieved on: 
Thursday, May 11, 2023
Immortalised cell line, PEGS, Workflow, CHO, B cell, Immunotherapy, Hynes Convention Center, TCR, APC, Expo, CELL, Chinese hamster ovary cell, Cell, Protein engineering, Conference, Pharmaceutical industry, Vaccine, Television, Purification

EMERYVILLE, Calif., May 11, 2023 /PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that it will participate in the 19th annual Protein Engineering & Cell Therapy Summit (PEGS) Conference and Expo being held from May 15-19 at the Hynes Convention Center in Boston, Mass.

Key Points: 
  • EMERYVILLE, Calif., May 11, 2023 /PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that it will participate in the 19th annual Protein Engineering & Cell Therapy Summit (PEGS) Conference and Expo being held from May 15-19 at the Hynes Convention Center in Boston, Mass.
  • During the time-course observation, >1,000 single T cells are monitored for their ability to kill APCs in co-culture, surface marker expression, and cytokine secretion.
  • Abstract: Microfluidic chips can be used to sort and clone CHO cells, perform miniaturized assays, and recover top performers.
  • In this presentation, data will be shared demonstrating how miniaturized quality assays enable selection of top performing clones within five days of cloning.

Orna Therapeutics to Present Progress of Lead Program ORN-101 at PEGS and ASGCT

Retrieved on: 
Thursday, May 4, 2023
PEGS, IRES, Therapy, Gene, Biotechnology, Infection, Cancer, DSM-IV codes, RNA, Doctor of Philosophy, CAR, Patient, Annual general meeting, Cell, American Society of Gene and Cell Therapy, Diagnosis, LNP, Protein, Society, Vaccine, Orna

CAMBRIDGE, Mass., May 4, 2023 /PRNewswire/ -- Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, today announced two presentations at the Protein Engineering Summit (PEGS) taking place May 15-19 in Boston as well as a poster presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles May 16-20. Orna is presenting preclinical results for ORN-101, an in situ CAR program in development, as well as further details about its platform.

Key Points: 
  • Orna is presenting preclinical results for ORN-101, an in situ CAR program in development, as well as further details about its platform.
  • "We are paving the way for advancements in RNA therapeutics that reach beyond infectious disease to treat cancer and genetic disorders," Robert Mabry, PhD, Chief Scientific Officer at Orna.
  • "Our ORN-101 program demonstrates the benefits of our platform's ability to create a paradigm-changing treatment with the characteristics we believe matter most to patients, including a rapid timeline from diagnosis to treatment, strong expression and tumor-killing potency at low dose, and a regimen without the harsh chemotherapeutic lymphodepletion protocols typically required for standard engineered cell therapies."
  • Details for the presentations are as follows:

Iris&Romeo Announces Its First-Ever Retail Partnership With Credo Beauty

Retrieved on: 
Tuesday, February 14, 2023
Sulfate, PEGS, Credo, Yoy, Lip, Vitamin C, Entrepreneurship, Face, SPF, Paraben, Multi, Partnership, Growth, DTC, Cosmetics

NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Iris&Romeo, the female-founded clean beauty brand known for creating the original skincare/makeup hybrids to help you consume less and get ready faster, announced today its first-ever retail launch with the leading clean beauty retailer, Credo Beauty. Starting today, Iris&Romeo will be debuting its full range of products in 11 stores nationwide in key locations including New York City, Brooklyn, Chicago, Los Angeles, San Francisco and Boston and will also be available for purchase at credobeauty.com.

Key Points: 
  • "When I launched the company it was my dream to have Credo Beauty as our first retail partner," said Michele Gough Baril, Founder of Iris&Romeo.
  • "Annie Jackson, Co-Founder and COO of Credo Beauty has had a clear vision of bringing together some of the most innovative, ethical, new brands in the space.
  • "Multi-use products are one of the fastest growing categories at Credo Beauty," said Meg Lim, Credo Beauty Color Merchant.
  • We look forward to beginning our retail entry with our exclusive partnership with a best-in-class retailer like Credo Beauty."